Vyleesi Compounded vs Branded: A Clinical Comparison of Bremelanotide

What Is Bremelanotide and How Does It Work?

Bremelanotide is a synthetic cyclic heptapeptide that acts as a nonselective agonist at melanocortin 3 and melanocortin 4 receptors in the central nervous system. Activation of these pathways modulates dopaminergic and noradrenergic signaling in limbic structures associated with sexual motivation. It does not act on sex hormone receptors, which separates it mechanistically from testosterone-based therapies for female sexual dysfunction.

Receptor Pharmacology

The melanocortin system involves at least five receptor subtypes (MC1R through MC5R). Bremelanotide binds MC3R and MC4R with nanomolar affinity. MC4R in the hypothalamus and mesolimbic regions appears to be the primary driver of its pro-sexual effect, based on animal knockout studies and dose-response modeling from early Phase I work. The FDA pharmacology review confirmed that peak plasma concentration occurs approximately 1 hour after subcutaneous injection, with a half-life of roughly 2.7 hours.

Why CNS Mechanism Matters for Compounding Comparisons

Because bremelanotide acts centrally, small differences in absorption rate or peptide purity between a compounded and branded product could shift the time-to-effect or the side-effect profile. A compounded peptide that is 90% pure still delivers 10% unknown impurities to a CNS-targeted pathway. That distinction is clinically meaningful in ways it would not be for, say, a topical emollient.

The RECONNECT Trials: What the Evidence Actually Shows

The RECONNECT program consisted of two parallel, randomized, double-blind, placebo-controlled Phase III trials (Study 301 and Study 302) published in Obstetrics and Gynecology in 2019. Combined, the trials enrolled 1,267 premenopausal women with generalized acquired HSDD across 93 U.S. Sites.

Primary Endpoints

The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score at 24 weeks. In the pooled analysis, bremelanotide produced a statistically significant improvement on both endpoints versus placebo (P<0.001 for each), with approximately 25% of treated women achieving a clinically meaningful response compared with 17% on placebo.

How the Numbers Look in Context

A 25% responder rate versus 17% on placebo represents a number needed to treat of roughly 13 for a clinically meaningful desire improvement. That is a modest but real effect. The FDA's position, articulated in the 2019 approval letter, was that the benefit-risk profile was acceptable for a condition with no other on-demand pharmacologic option approved at the time. Flibanserin (Addyi), approved in 2015 for the same indication, requires daily dosing and carries a black-box warning for hypotension with alcohol. Bremelanotide is taken on demand, which many women and prescribers prefer.

What RECONNECT Did Not Study

The trials did not include postmenopausal women, women with surgical menopause, or women on hormonal contraceptives who were not otherwise eligible. Efficacy data in those populations does not exist from controlled trials, which matters when a compounding pharmacy's marketing implies broader use.

FDA-Approved Vyleesi: Formulation, Delivery, and Labeling

Vyleesi is supplied as a single-dose, prefilled auto-injector delivering 1.75 mg bremelanotide in 0.4 mL of aqueous solution for subcutaneous injection into the abdomen or thigh. The product label specifies injection 45 minutes before anticipated sexual activity and limits use to no more than one dose per 24-hour period.

Stability and Excipients

The branded formulation uses a citrate-buffered solution at pH 4.0 to 5.0 with mannitol as a tonicity agent. This specific buffer system was selected during Phase II development to minimize degradation of the cyclic peptide structure at room temperature storage (up to 77°F / 25°C). Stability data submitted to the FDA covers 24 months at labeled conditions.

Blood Pressure Monitoring Requirement

Vyleesi's label carries a boxed warning about transient increases in blood pressure. In RECONNECT, mean systolic blood pressure rose by approximately 6 mmHg and mean diastolic by approximately 3 mmHg, peaking at 4 hours post-dose and resolving within 12 hours. Prescribers must assess cardiovascular risk before initiating therapy. Women with established cardiovascular disease are excluded.

Compounded Bremelanotide: Regulatory Status and What It Means

Compounded bremelanotide is not FDA-approved. It is prepared by 503A or 503B compounding pharmacies under the authority of the Federal Food, Drug, and Cosmetic Act, which exempts compounded drugs from FDA's new drug approval process provided certain conditions are met. The FDA has stated that compounding a copy of a commercially available drug product is generally not permitted under 503A unless the patient has a documented allergy or clinical need that the branded product cannot meet.

The 503A vs 503B Distinction

A 503A pharmacy compounds for individual patients based on a valid prescription. A 503B outsourcing facility can compound in bulk without a patient-specific prescription but must register with the FDA and comply with current good manufacturing practices (cGMP). FDA inspections of 503B facilities have found sterility and potency deficiencies; a 2023 FDA warning letter to one outsourcing facility cited sub-potent peptide preparations. Not all compounding pharmacies operate at the same standard.

Purity, Potency, and the Peptide Problem

Synthetic peptides like bremelanotide are sensitive to oxidation, hydrolysis, and racemization during manufacturing. Without the same analytical method validation that supports an NDA filing, a compounding pharmacy may not detect a 15% drop in potency or the presence of a diastereomeric impurity. The U.S. Pharmacopeia (USP) publishes compounding standards, but compliance with USP chapters is voluntary for most 503A pharmacies unless state law mandates it.

No Head-to-Head Trial Data

No published randomized trial has compared compounded bremelanotide directly to Vyleesi. Any claim that a compounded product is "equivalent" to Vyleesi rests on assumed bioequivalence rather than demonstrated bioequivalence. FDA bioequivalence standards (90% confidence interval of the test-to-reference ratio for AUC and Cmax within 80 to 125%) have not been applied to any compounded bremelanotide product.

Pharmacokinetics: Branded vs Compounded Considerations

The FDA-approved labeling for Vyleesi reports the following pharmacokinetic parameters after a single 1.75 mg subcutaneous dose in healthy women: Cmax of approximately 4.5 ng/mL, Tmax of approximately 1 hour, AUC(0-inf) of approximately 16.6 ng·h/mL, and a terminal half-life of approximately 2.7 hours. These values were established across multiple PK studies submitted in the NDA package reviewed by FDA in 2018 to 2019.

Why Injection Site and Vehicle Matter

Subcutaneous absorption of peptides is sensitive to the vehicle, injection depth, and local blood flow. A compounded formulation using a different buffer, pH, or preservative system may shift Tmax by 15 to 30 minutes, which is clinically relevant for a drug whose label says to inject 45 minutes before activity. A preparation with a lower pH could also increase injection-site pain and local inflammatory reactions relative to the labeled product.

Dose Accuracy in Auto-Injector vs Vial

Vyleesi's auto-injector is engineered to deliver a precise 0.4 mL volume. Compounded bremelanotide is often supplied as a lyophilized powder requiring reconstitution, or as a multi-dose vial. User error in measuring a dose from a vial, particularly when patients self-administer, could result in doses meaningfully above or below 1.75 mg. Over-dosing increases nausea risk. Under-dosing reduces efficacy.

Side-Effect Profiles: What Trials Show and What Compounds May Change

The adverse effect data from RECONNECT are the only controlled, large-scale safety data available for bremelanotide at the 1.75 mg dose. Nausea occurred in 40% of women in the bremelanotide arm versus 1% with placebo; 13% of treated women used antiemetic medication. Flushing occurred in 20%, and injection-site bruising or pain occurred in roughly 11%.

Nausea Management

The RECONNECT protocol recommended pre-treatment with ondansetron 8 mg orally 30 minutes before injection in women who experienced significant nausea. That approach reduced dropout due to nausea from approximately 18% to approximately 8% in the open-label extension. Prescribers initiating either branded or compounded bremelanotide should proactively address nausea management at the first visit.

Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breasts was reported in about 1% of women in the branded trials with repeated dosing. This finding is consistent with melanocortin pathway activation of MC1R on melanocytes; the RECONNECT label advises against use in women with a history of hyperpigmentation disorders. The signal exists regardless of whether the formulation is branded or compounded, but compounded products carry no label to communicate this risk to patients.

Cost, Access, and Insurance Coverage

Vyleesi's list price at launch was approximately $800 per dose (4 auto-injectors per carton at approximately $3,200 per carton). Commercial insurance coverage has been inconsistent; as of 2024, most major PBMs do not include Vyleesi on their standard formularies without prior authorization. Patient assistance programs through the manufacturer (Palatin Technologies / AMAG / Cosette Pharmaceuticals) have reduced out-of-pocket costs for some commercially insured patients.

Why Compounded Versions Are Cheaper

Compounding pharmacies do not pay for clinical trials, FDA submission fees, or branded marketing. A compounded 1.75 mg dose typically runs $30 to $80 through telehealth platforms. That price differential is real and matters for access, particularly for women without prescription drug insurance. The cost saving, however, does not address purity verification, lot-to-lot consistency, or the absence of post-marketing surveillance data.

Prescriber Liability Considerations

A prescriber who writes for a compounded copy of Vyleesi when the branded product is commercially available accepts greater medicolegal exposure if an adverse event occurs. The FDA's guidance on compounding clearly states that a compounded drug is not held to the same safety and efficacy standard as an approved product. Prescribers should document the clinical rationale (cost barrier, allergy, inability to obtain branded product) in the chart.

Patient Selection: Who Is a Candidate?

The RECONNECT inclusion criteria define the evidence-supported population: premenopausal women, aged 18 to 55, with a DSM-5 diagnosis of generalized acquired HSDD, with at least 6 months of symptoms, and with personal distress attributed to low desire. The ISSWSH (International Society for the Study of Women's Sexual Health) process of care guideline recommends ruling out hormonal causes, relationship factors, and mood disorders before initiating pharmacologic therapy.

Absolute Contraindications

Women with known cardiovascular disease, uncontrolled hypertension (systolic >150 mmHg or diastolic >95 mmHg), or concurrent use of naltrexone should not receive bremelanotide in any form. The interaction between bremelanotide and naltrexone is pharmacokinetic: bremelanotide reduces naltrexone Cmax by approximately 35%, which could compromise opioid use disorder treatment.

When Compounded May Be the Practical Option

For a premenopausal woman with a confirmed HSDD diagnosis, documented distress, no cardiovascular contraindications, and no insurance coverage for Vyleesi, a compounded formulation from an FDA-registered 503B outsourcing facility may be the only financially accessible option. In that scenario, the prescriber should verify the pharmacy's registration status on the FDA's 503B database, request a certificate of analysis for the specific lot, and document the access barrier in the record.

How Clinicians Should Approach the Conversation

Patients comparing Vyleesi to compounded bremelanotide online often arrive with cost-driven questions. A structured clinical conversation covers five points:

1. Confirm diagnosis. HSDD has specific DSM-5 criteria. Not all low desire is HSDD, and bremelanotide has no evidence in non-HSDD female sexual dysfunction.
2. Screen cardiovascular risk. A baseline blood pressure reading is non-negotiable before the first dose.
3. Discuss nausea proactively. Pre-treatment antiemetic therapy reduces the dropout rate substantially.
4. Address cost transparently. If Vyleesi is unaffordable without assistance, discuss 503B compounding with verification steps rather than dismissing the patient's option.
5. Set realistic expectations. A number needed to treat of 13 means many women will not respond. The RECONNECT investigators noted that women who did respond typically saw improvement within the first four doses, suggesting a practical 4-dose trial period before assessing non-response.

The American College of Obstetricians and Gynecologists (ACOG) advises in their female sexual dysfunction practice bulletin: "Pharmacologic therapy should be considered adjunctive to, not a replacement for, psychosexual counseling and treatment of contributing medical conditions." The full practice bulletin is available through the ACOG clinical guidance portal.

Compounding Pharmacy Verification: A Practical Checklist

Before writing a prescription for compounded bremelanotide, prescribers should complete the following verification steps. Each step corresponds to a specific regulatory resource.

• Confirm 503B registration: Search the FDA's list of registered outsourcing facilities at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.
• Review inspection history: FDA posts 483 observations and warning letters by facility at fda.gov/inspections-compliance-enforcement-and-criminal-investigations.
• Request a certificate of analysis (CoA): A legitimate 503B facility issues lot-specific CoAs with HPLC purity data, residual solvent testing, and endotoxin limits. USP Chapter 797 sets sterility and endotoxin standards for sterile compounded preparations.
• Verify storage and shipping conditions: Compounded peptides shipped without cold-chain documentation may arrive degraded.